Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-11-23
Based on 1083 first isolates · ED · Cystitis (lower UTI) · 2024-11-24 → 2025-11-23
Emergency department
Per-organism detail: ED urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 85 % (83 %–87 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (6 %), Pseudomonas aeruginosa (6 %), Klebsiella pneumoniae (3 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
85 %
91 %
n = 97
meropenem MEM
trend · Escherichia coli reserve
85 %
87 %
n = 97
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
81 %
86 %
n = 97
ciprofloxacin CIP
trend · Escherichia coli
78 %
77 %
n = 97
mecillinam MEC
trend · Escherichia coli lower UTI only
77 %
80 %
n = 97
ceftriaxone CRO
trend · Escherichia coli
76 %
80 %
n = 97
trimethoprim TMP
trend · Escherichia coli lower UTI only
72 %
72 %
n = 97
72 %
78 %
n = 97
54 %
54 %
n = 97
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
13 %
12 %
n = 97
5 %
2 %
n = 97
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
2 %
1 %
n = 97

Most likely organisms for this profile

Escherichia coli
57 %
Enterococcus faecalis
10 %
Klebsiella pneumoniae
10 %
Proteus mirabilis
6 %
Pseudomonas aeruginosa
6 %
Klebsiella oxytoca
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.